[go: up one dir, main page]

MX2019009200A - Composiciones y métodos para inhibir el reticulón 4. - Google Patents

Composiciones y métodos para inhibir el reticulón 4.

Info

Publication number
MX2019009200A
MX2019009200A MX2019009200A MX2019009200A MX2019009200A MX 2019009200 A MX2019009200 A MX 2019009200A MX 2019009200 A MX2019009200 A MX 2019009200A MX 2019009200 A MX2019009200 A MX 2019009200A MX 2019009200 A MX2019009200 A MX 2019009200A
Authority
MX
Mexico
Prior art keywords
compositions
methods
reticulon
inhibiting
inhibiting reticulon
Prior art date
Application number
MX2019009200A
Other languages
English (en)
Inventor
K Nomura Daniel
A Bateman Leslie
R Huffman Tucker
K Miyamoto David
A Olzmann James
B Nguyen Truc
M Roberts Allison
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2019009200A publication Critical patent/MX2019009200A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/09—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen en la presente, entre otros, composiciones y métodos útiles para inhibir reticulón 4 (RTN4).
MX2019009200A 2017-02-03 2018-02-02 Composiciones y métodos para inhibir el reticulón 4. MX2019009200A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762454681P 2017-02-03 2017-02-03
US201762471865P 2017-03-15 2017-03-15
PCT/US2018/016650 WO2018144870A1 (en) 2017-02-03 2018-02-02 Compositions and methods for inhibiting reticulon 4

Publications (1)

Publication Number Publication Date
MX2019009200A true MX2019009200A (es) 2019-10-21

Family

ID=63040209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009200A MX2019009200A (es) 2017-02-03 2018-02-02 Composiciones y métodos para inhibir el reticulón 4.

Country Status (11)

Country Link
US (1) US20200062696A1 (es)
EP (1) EP3576728A4 (es)
JP (1) JP2020506935A (es)
KR (1) KR20190126074A (es)
CN (1) CN110461322A (es)
AU (1) AU2018215447A1 (es)
BR (1) BR112019016132A2 (es)
CA (1) CA3051587A1 (es)
MX (1) MX2019009200A (es)
SG (1) SG11201906671SA (es)
WO (1) WO2018144870A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53433A (fr) * 2018-08-24 2021-06-30 Xeniopro GmbH Éthers phénoxy(hétéro)aryle à activité antiproliférative
AU2020415446A1 (en) * 2019-12-24 2022-07-14 Dana-Farber Cancer Institute, Inc. Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof
CN119318708B (zh) * 2024-10-15 2025-10-10 中国科学技术大学 Eya3作为靶点在宫颈癌治疗中的应用
CN121202963A (zh) * 2025-11-28 2025-12-26 山东省海洋科学研究院(青岛国家海洋科学研究中心) 一种卤虫抗氧化肽肽段、抗氧化肽、制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102790A (en) * 1991-09-17 1996-01-31 Roussel Uclaf 3-Cycloalkyl-prop-2- enamide derivatives
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
US7928127B2 (en) * 2005-05-19 2011-04-19 Notre Dame University Inhibitors of matrix metallaproteinases
US8828390B2 (en) * 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
WO2012164103A2 (en) * 2011-06-03 2012-12-06 Universität Zürich Blockers of the nogo-a s1pr pathway for the treatment of diseases characterized by neuronal damage and lack of subsequent repair
MX353205B (es) * 2011-08-03 2018-01-08 Univ Nat Taiwan Agonistas de proteína-tirosina-fosfatasa-1 que contiene homología src-2 y métodos de tratamiento que usan los mismos.
US9353062B2 (en) * 2012-04-04 2016-05-31 Hangzhouderenyucheng Biotechnology Ltd Substituted quinolines as bruton's tyrosine kinases inhibitors
EP3033625B1 (en) * 2013-08-13 2020-01-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
KR102408123B1 (ko) * 2014-02-28 2022-06-10 고쿠리츠다이가쿠호진 도호쿠다이가쿠 아마이드 유도체
US10294205B2 (en) * 2014-04-16 2019-05-21 Nanyang Technological University Allenamide as an orthogonal handle for selective modification of cysteine in peptides and proteins
KR20170103838A (ko) * 2015-01-23 2017-09-13 컨플루언스 라이프 사이언시스, 인코포레이티드 염증 및 암의 치료를 위한 헤테로시클릭 itk 저해제
JP6953400B2 (ja) * 2015-10-22 2021-10-27 ザ スクリプス リサーチ インスティテュート システイン反応性プローブとその使用

Also Published As

Publication number Publication date
BR112019016132A2 (pt) 2020-04-07
KR20190126074A (ko) 2019-11-08
JP2020506935A (ja) 2020-03-05
CA3051587A1 (en) 2018-08-09
AU2018215447A1 (en) 2019-08-08
WO2018144870A8 (en) 2019-09-06
SG11201906671SA (en) 2019-08-27
CN110461322A (zh) 2019-11-15
US20200062696A1 (en) 2020-02-27
EP3576728A4 (en) 2020-08-12
WO2018144870A1 (en) 2018-08-09
EP3576728A1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
IL285302A (en) Compounds, preparations and methods
SG11202104326TA (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
MX2019007021A (es) Anticuerpos il-11ra.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
NZ763551A (en) Compounds useful for inhibiting cdk7
MX2019007020A (es) Anticuerpos il-11.
SG10201803042PA (en) Anti-tim-3 antibodies
MY191581A (en) Anti-pd-1 antibodies
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
SG10201902326XA (en) Mk2 inhibitors and uses thereof
SG10201909805XA (en) Surface modified polymer compositions
IL284800A (en) Methods, uses and compositions
GB202017595D0 (en) Compositions, and methods and uses relating thereto
ZA201904387B (en) Compositions and methods for treating, ameliorating and preventing h. pylori
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
ZA201905895B (en) Kits and methods for preparing pathogen-inactivated platelet compositions
GB2568181A (en) Wheat
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
GB2576614B (en) Compositions, uses and methods
PH12017501864A1 (en) Compositions and methods for treating autism
MX2021003159A (es) Microemulsiones que contienen antioxidantes.
MX2019009200A (es) Composiciones y métodos para inhibir el reticulón 4.
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
IL288864A (en) Treatment that includes sglt inhibitors, for example sglt 1/2 inhibitors
IL287120A (en) Compounds, preparations and methods